Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials

Abstract

Antimalarials are first-line systemic therapy for cutaneous lupus erythematosus (CLE). While some patients unresponsive to hydroxychloroquine (HCQ) alone benefit from the addition of quinacrine (QC), a subset of patients is refractory to both antimalarials.

Document Details

Document Type
Pub Defense Publication
Publication Date
Mar 08, 2022
Source ID
10.1177/09612033221084093

Entities

People

  • Jay Patel
  • Krisha Desai
  • Kristen L Chen
  • Majid Zeidi
  • Rachel E. Lim
  • Srita Chakka
  • Victoria P. Werth
  • hee joo kim

Organizations

  • Alliance for Lupus Research
  • Atlanta VA Medical Center
  • Istituto Superiore di Sanità
  • United States Department of Defense
  • University of Pennsylvania

Tags

Fields of Study

  • Medicine

Readers

  • Neurological Diseases/Conditions/Disorders
  • Oncology
  • Parasitology and Pharmacology of Malaria.